BioWorld

March 13, 2006

View Archived Issues

NPS Falls On Preos Approvable Letter; Safety Concerns Cited

NPS Pharmaceuticals Inc. received an approvable letter for Preos, its parathyroid hormone to reduce fracture risk, but the company’s shares fell 37.5 percent amid safety concerns raised by the FDA. (BioWorld Today) Read More

Insmed Offering Raises $37.2M To Fund iPLEX, Other Programs

Read More

A Kinder, Gentler Place For Biotech Hallmark: Start-ups

Read More

Corautus Brings In $26.5M To Fund VEGF-2 Program

Read More

Other News To Note

Read More